Better Dividend Stock: AbbVie or Viatris?
AbbVie (ABBV 0.14%) and Viatris (VTRS 1.09%) have a lot more in common than first glances would suggest. The two were both spun off from larger companies and now deliver above-average dividend yields. As pharmaceutical companies, they provide the potential for steady growth and income that many…#dividend #humira #abbvie #viatris #abbv #vtrs #rinvoq #skyrizi #biosimilarcompetition #drughumira (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2022 Category: Consumer Health News Source Type: news
UnitedHealth ’s Optum Rx To Coax Patients To Less Pricey Biosimilars Of Abbvie’s Humira
UnitedHealth Group ’s OptumRx will put biosimilar versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as the brand” on the PBM’s formulary in 2023. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 15, 2022 Category: Pharmaceuticals Authors: Bruce Japsen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma Source Type: news
Another Adalimumab Biosimilar Seems Set for Interchangeability
(MedPage Today) -- PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested.
A pivotal trial involving nearly 445 rheumatoid arthritis... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 14, 2022 Category: Rheumatology Source Type: news
NHS drive to save £150million for cheaper 'biosimilars' may have left THOUSANDS in agony
Amanda Wayne (pictured), 34, a design studio manager from Enfield, was swapped from Humira to Amgevita for her Crohn's disease in February 2019. (Source: the Mail online | Health)
Source: the Mail online | Health - October 29, 2022 Category: Consumer Health News Source Type: news
JAK Inhibitors Show No Excess CV Safety Signal JAK Inhibitors Show No Excess CV Safety Signal
Compared with adalimumab, JAK inhibitors presented no higher risk for major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 20, 2022 Category: Cardiology Tags: Rheumatology News Source Type: news
No Special Heart Risk With JAK Inhibitors, Study Finds
(MedPage Today) -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 7, 2022 Category: Cardiology Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Olokizumab Proves Noninferior to Adalimumab for RA Olokizumab Proves Noninferior to Adalimumab for RA
The manufacturer of olokizumab is expected to file for approval in the United States early next year, and the drug could add a new option for patients for whom methotrexate alone doesn ' t work.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
IBD Biologics After COVID; Cutting Endoscopy Waste; New Humira Biosimilar OK'd
(MedPage Today) -- How soon after a COVID-19 infection is it OK to administer biologics for patients with inflammatory bowel disease (IBD)? (Clinical Gastroenterology and Hepatology)
Compared with second-dose side effects, gastrointestinal symptoms... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 26, 2022 Category: Gastroenterology Source Type: news
Olokizumab Tops Placebo for RA Patients Receiving Methotrexate
THURSDAY, Aug. 25, 2022 -- Olokizumab is superior to placebo and noninferior to adalimumab in patients with rheumatoid arthritis receiving maintenance methotrexate, according to a study published in the Aug. 25 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2022 Category: Pharmaceuticals Source Type: news
Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis
(MedPage Today) -- A new type of anti-interleukin-6 (IL-6) biologic called olokizumab was as effective as adalimumab (Humira) in rheumatoid arthritis patients who needed a step up from methotrexate monotherapy, results from a phase III trial indicated... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 25, 2022 Category: Rheumatology Source Type: news
FDA Approves Adalimumab Biosimilar in High-Concentration Form FDA Approves Adalimumab Biosimilar in High-Concentration Form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 17, 2022 Category: Dermatology Tags: Rheumatology News Alert Source Type: news
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Humira ® Biosimilar Hadlima™ (adalimumab-bwwd)
INCHEON, Korea and Jersey City, N.J., United States– August 17, 2022– Samsung Bioepis Co., Ltd. and Organon& Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 17, 2022 Category: Drugs & Pharmacology Source Type: news
Which Biologics Stick Longest for Psoriasis?
(MedPage Today) -- Patients stayed longer with guselkumab (Tremfya) for psoriasis treatment than any other biologic drug, while adalimumab (Humira) was dropped the quickest, British registry data indicated.
With ustekinumab (Stelara) chosen arbitrarily... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 6, 2022 Category: Dermatology Source Type: news
Two Biologics Work Equally Well for Active Crohn's Disease Two Biologics Work Equally Well for Active Crohn's Disease
For adults with moderate to severe Crohn ' s disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
